P K Brastianos on CNS Metastases: Understanding Their Evolution and the Clinical Implications

P K Brastianos on CNS Metastases: Understanding Their Evolution and the Clinical Implications

Recent : AACR Annual Meeting 2022
Priscilla K. Brastianos, MD, of Harvard Medical School and Massachusetts General Hospital, talks about her efforts to better understand how brain metastases evolve genomically and to test such agents as abemaciclib, paxalisib, and entrectinib, which may stop their growth. Palbociclib, a CDK inhibitor, has already shown potential benefit. A national cooperative group trial is underway in multiple centers to identify novel treatments for patients with brain metastases, who typically have a poor prognosis (Abstract SY38).

https://ascopost.com/videos/aacr-annual-meeting-2022/priscilla-brastianos-on-cns-metastases-understanding-their-evolution-and-the-clinical-implications/

Note: ASCO Meeting - Education Session EY51
Molecular Drivers in the Evolution of Brain Metastases and Implications on Treatment
Speaker : P K Brastianos MD

Regards.